Moreover, IHC assay demonstrated low expression of DLG5 and PRDM16 in trastuzumab non-response HER2-positive breast cancer patients but high expression of DLG5 and PRDM16 in trastuzumab-response HER2-positive breast cancer patients (Fig. 9E). Here, ERBB2 is linked to breast carcinoma.